Registry analysis reveals survival patterns and mortality risk factors after heart pump placement, highlighting critical prognostic markers in high-risk advanced heart failure.
Background: Durable left ventricular assist device (LVAD) therapy was introduced in Korea in 2018 within a transplant environment characterized by frequent preoperative extracorporeal membrane oxygenation (ECMO) support. We evaluated nationwide outcomes and predictors of mortality after LVAD implantation.
No takes yet. Share an insight, caveat, or question.
Cho et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: